Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPNMB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPNMB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GPNMB Products |
| Gene Delivery | GPNMB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GPNMB Products |
| Benchmark Ab | Anti-GPNMB (Sequence of Glembatumumab) Recombinant positive control. |
View GPNMB Products |
| Validator | GPNMB siRNA Set For knockdown verification. |
View GPNMB Products |
| Related Target A | TROP2 Synergistic ADC target for Triple-Negative Breast Cancer (TNBC) and solid tumors. |
View TROP2 Products |
| Related Target B | SNCA (Alpha-synuclein) Core interacting protein in Parkinson's disease pathogenesis. |
View SNCA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Toxicology Eval | Human, Mouse, and Cynomolgus GPNMB ortholog proteins available with >95% purity |
| Glycosylation-Dependent Epitope Binding | HEK293 Expressed (Native Glycosylation) ensuring proper conformation |
| Lack of Reliable Assay Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives in Screening | Validated siRNA included for precise specificity checks in target-negative models |
Live GPNMB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPNMB therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation Antibody-Drug Conjugates (ADCs) and bispecifics. GPNMB (Glycoprotein Nonmetastatic Melanoma Protein B) is highly overexpressed in aggressive solid tumors like TNBC, melanoma, and glioblastoma. As first-generation therapies provided crucial clinical proof-of-concept regarding target safety, the next wave of R&D is targeting optimized linker-payload stability, improved internalization rates, and novel indications in neurodegenerative diseases like Parkinson's, where GPNMB interacts with alpha-synuclein.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Celldex, AbbVie, Pearl River | TNBC, Melanoma, Squamous Cell | Internalization Assay (Need high-purity HEK293 GPNMB ECD-Fc) |
| Monoclonal Antibody | Sanofi, Genzyme | Parkinson's Disease (Neuro) | Affinity/Cross-reactivity Assay (Need Cyno/Human GPNMB orthologs) |
| CAR-T / Bispecifics | Academic / Early Biotech | Glioblastoma | Cell Line Validation (Need Lentivirus for Stable Cell Line generation) |